Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression

•Pentosan polysulfate ameliorated clinical signs of experimental colitis in mice.•It preserved colon structure and enhanced the mucosal proliferative capacity.•It augmented the colonic expression of the anti-inflammatory IL-35 gene.•It showed colonic reduction of the pro-inflammatory cytokine “IL-6”...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International immunopharmacology 2022-05, Vol.106, p.108620-108620, Article 108620
Hauptverfasser: Ashour, Rehab H., Hazem, Noha M., AbdElfattah, Amany A., El-Kady, Rania A., Elmasry, Ahlam
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 108620
container_issue
container_start_page 108620
container_title International immunopharmacology
container_volume 106
creator Ashour, Rehab H.
Hazem, Noha M.
AbdElfattah, Amany A.
El-Kady, Rania A.
Elmasry, Ahlam
description •Pentosan polysulfate ameliorated clinical signs of experimental colitis in mice.•It preserved colon structure and enhanced the mucosal proliferative capacity.•It augmented the colonic expression of the anti-inflammatory IL-35 gene.•It showed colonic reduction of the pro-inflammatory cytokine “IL-6” concentration.•It showed more pounced effects upon combination with acetylsalicylic acid. Ulcerative colitis (UC) primarily affects the mucosa of the distal colon. Dysregulated immune response in genetically-prone persons is claimed to be responsible for chronic intestinal inflammation. This study aimed to explore the efficacy and the hematological effects of pentosan polysulfate sodium (PPS) in a dextran sulfate sodium (DSS)-induced colitis model. Forty C57BL/6 female mice were equally divided into five groups: control group, DSS-colitis group, DSS-colitis treated with 5-aminosalicylic acid, DSS-colitis treated with PPS, and DSS-colitis treated with both drugs. Disease activity index (DAI) and colon length were calculated. Colonic IL-6 and IL-35 levels were assayed by ELISA. IL-35 gene expression was evaluated by qRT-PCR. Colon tissue samples were examined by H&E stain and immunohistochemistry (IHC) of Ki67. The colitis group subjected to combined treatment showed the best outcome with significant improvement of DAI and increased colon length. Colonic IL-6 was significantly lower in both PPS- and combination-treated groups accompanied by a significantly higher IL-35 level and its EBI3 subunit mRNA expression. However, the PPS-treated colitis group showed higher gene expression of IL-35 EBI3 subunit by 1.5-fold compared with the combined group. The colon mucosa and crypts were significantly preserved in mice treated with both drugs with the best Ki67 positive cell density. PPS is a safe and promising drug in the treatment of UC as it exerted the best positive effect on the anti-inflammatory IL-35 level and gene expression. However, superior improvement of DAI was seen when PPS was added to ASA with a greater mucosal proliferation and repair.
doi_str_mv 10.1016/j.intimp.2022.108620
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2636142796</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576922001047</els_id><sourcerecordid>2636142796</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-a0cf8b46dfc9e68fb5b574e7f9aa38cda04e6493b2e360a0290034772f4154063</originalsourceid><addsrcrecordid>eNp9kd2K1TAUhYsozjj6BiIBb7zpMf9JEYTD-DdwwIGj1yFNdzSHtqlJK54n8LVN7eiFF15sEna-tXbYq6qeErwjmMiXp10Y5zBMO4opLS0tKb5XXRKtdE0UFvfLXUhVCyWbi-pRzieMS5-Th9UFE5QrLZrL6uctjHPMdkS3sT_npfd2BnSMXVgGZJcvQ3nOaP4KayU7wTIHh8B7cDOKHol6P4SxGPTBnUuhvQsdCiN6czwiF_swh4yG2EH_6rdLij2suptDzQSCH1OCnEMcH1cPvO0zPLk7r6rP795-uv5QHz6-v7neH2rHsJhri53XLZeddw1I7VvRCsVB-cZapl1nMQfJG9ZSYBJbTBuMGVeKek4Ex5JdVS823ynFbwvk2QwhO-h7O0JcsqGSScKpalb0-T_oKS5pLL8rlNBUN4TpQvGNcinmnMCbKYXBprMh2KxBmZPZgjJrUGYLqsie3Zkv7QDdX9GfZArwegOgbON7gGSyCzA66EIquzddDP-f8AubCKXe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2658289138</pqid></control><display><type>article</type><title>Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression</title><source>Elsevier ScienceDirect Journals</source><creator>Ashour, Rehab H. ; Hazem, Noha M. ; AbdElfattah, Amany A. ; El-Kady, Rania A. ; Elmasry, Ahlam</creator><creatorcontrib>Ashour, Rehab H. ; Hazem, Noha M. ; AbdElfattah, Amany A. ; El-Kady, Rania A. ; Elmasry, Ahlam</creatorcontrib><description>•Pentosan polysulfate ameliorated clinical signs of experimental colitis in mice.•It preserved colon structure and enhanced the mucosal proliferative capacity.•It augmented the colonic expression of the anti-inflammatory IL-35 gene.•It showed colonic reduction of the pro-inflammatory cytokine “IL-6” concentration.•It showed more pounced effects upon combination with acetylsalicylic acid. Ulcerative colitis (UC) primarily affects the mucosa of the distal colon. Dysregulated immune response in genetically-prone persons is claimed to be responsible for chronic intestinal inflammation. This study aimed to explore the efficacy and the hematological effects of pentosan polysulfate sodium (PPS) in a dextran sulfate sodium (DSS)-induced colitis model. Forty C57BL/6 female mice were equally divided into five groups: control group, DSS-colitis group, DSS-colitis treated with 5-aminosalicylic acid, DSS-colitis treated with PPS, and DSS-colitis treated with both drugs. Disease activity index (DAI) and colon length were calculated. Colonic IL-6 and IL-35 levels were assayed by ELISA. IL-35 gene expression was evaluated by qRT-PCR. Colon tissue samples were examined by H&amp;E stain and immunohistochemistry (IHC) of Ki67. The colitis group subjected to combined treatment showed the best outcome with significant improvement of DAI and increased colon length. Colonic IL-6 was significantly lower in both PPS- and combination-treated groups accompanied by a significantly higher IL-35 level and its EBI3 subunit mRNA expression. However, the PPS-treated colitis group showed higher gene expression of IL-35 EBI3 subunit by 1.5-fold compared with the combined group. The colon mucosa and crypts were significantly preserved in mice treated with both drugs with the best Ki67 positive cell density. PPS is a safe and promising drug in the treatment of UC as it exerted the best positive effect on the anti-inflammatory IL-35 level and gene expression. However, superior improvement of DAI was seen when PPS was added to ASA with a greater mucosal proliferation and repair.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2022.108620</identifier><identifier>PMID: 35247859</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Cell density ; Colitis ; Colon ; Combined treatment ; Crypts ; Dextran ; Dextran sulfate ; Dextrans ; Drugs ; Enzyme-linked immunosorbent assay ; Gene expression ; Immune response ; Immune system ; Immunohistochemistry ; Immunosuppressive agents ; Inflammatory bowel disease ; Inflammatory bowel diseases ; Interleukin 6 ; Interleukin-35 ; Ki67 ; Mucosa ; Pentosan polysulfate ; Sodium ; Ulcerative colitis</subject><ispartof>International immunopharmacology, 2022-05, Vol.106, p.108620-108620, Article 108620</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV May 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c305t-a0cf8b46dfc9e68fb5b574e7f9aa38cda04e6493b2e360a0290034772f4154063</citedby><cites>FETCH-LOGICAL-c305t-a0cf8b46dfc9e68fb5b574e7f9aa38cda04e6493b2e360a0290034772f4154063</cites><orcidid>0000-0001-9744-4609</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1567576922001047$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35247859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ashour, Rehab H.</creatorcontrib><creatorcontrib>Hazem, Noha M.</creatorcontrib><creatorcontrib>AbdElfattah, Amany A.</creatorcontrib><creatorcontrib>El-Kady, Rania A.</creatorcontrib><creatorcontrib>Elmasry, Ahlam</creatorcontrib><title>Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•Pentosan polysulfate ameliorated clinical signs of experimental colitis in mice.•It preserved colon structure and enhanced the mucosal proliferative capacity.•It augmented the colonic expression of the anti-inflammatory IL-35 gene.•It showed colonic reduction of the pro-inflammatory cytokine “IL-6” concentration.•It showed more pounced effects upon combination with acetylsalicylic acid. Ulcerative colitis (UC) primarily affects the mucosa of the distal colon. Dysregulated immune response in genetically-prone persons is claimed to be responsible for chronic intestinal inflammation. This study aimed to explore the efficacy and the hematological effects of pentosan polysulfate sodium (PPS) in a dextran sulfate sodium (DSS)-induced colitis model. Forty C57BL/6 female mice were equally divided into five groups: control group, DSS-colitis group, DSS-colitis treated with 5-aminosalicylic acid, DSS-colitis treated with PPS, and DSS-colitis treated with both drugs. Disease activity index (DAI) and colon length were calculated. Colonic IL-6 and IL-35 levels were assayed by ELISA. IL-35 gene expression was evaluated by qRT-PCR. Colon tissue samples were examined by H&amp;E stain and immunohistochemistry (IHC) of Ki67. The colitis group subjected to combined treatment showed the best outcome with significant improvement of DAI and increased colon length. Colonic IL-6 was significantly lower in both PPS- and combination-treated groups accompanied by a significantly higher IL-35 level and its EBI3 subunit mRNA expression. However, the PPS-treated colitis group showed higher gene expression of IL-35 EBI3 subunit by 1.5-fold compared with the combined group. The colon mucosa and crypts were significantly preserved in mice treated with both drugs with the best Ki67 positive cell density. PPS is a safe and promising drug in the treatment of UC as it exerted the best positive effect on the anti-inflammatory IL-35 level and gene expression. However, superior improvement of DAI was seen when PPS was added to ASA with a greater mucosal proliferation and repair.</description><subject>Cell density</subject><subject>Colitis</subject><subject>Colon</subject><subject>Combined treatment</subject><subject>Crypts</subject><subject>Dextran</subject><subject>Dextran sulfate</subject><subject>Dextrans</subject><subject>Drugs</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Gene expression</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunohistochemistry</subject><subject>Immunosuppressive agents</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory bowel diseases</subject><subject>Interleukin 6</subject><subject>Interleukin-35</subject><subject>Ki67</subject><subject>Mucosa</subject><subject>Pentosan polysulfate</subject><subject>Sodium</subject><subject>Ulcerative colitis</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kd2K1TAUhYsozjj6BiIBb7zpMf9JEYTD-DdwwIGj1yFNdzSHtqlJK54n8LVN7eiFF15sEna-tXbYq6qeErwjmMiXp10Y5zBMO4opLS0tKb5XXRKtdE0UFvfLXUhVCyWbi-pRzieMS5-Th9UFE5QrLZrL6uctjHPMdkS3sT_npfd2BnSMXVgGZJcvQ3nOaP4KayU7wTIHh8B7cDOKHol6P4SxGPTBnUuhvQsdCiN6czwiF_swh4yG2EH_6rdLij2suptDzQSCH1OCnEMcH1cPvO0zPLk7r6rP795-uv5QHz6-v7neH2rHsJhri53XLZeddw1I7VvRCsVB-cZapl1nMQfJG9ZSYBJbTBuMGVeKek4Ex5JdVS823ynFbwvk2QwhO-h7O0JcsqGSScKpalb0-T_oKS5pLL8rlNBUN4TpQvGNcinmnMCbKYXBprMh2KxBmZPZgjJrUGYLqsie3Zkv7QDdX9GfZArwegOgbON7gGSyCzA66EIquzddDP-f8AubCKXe</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Ashour, Rehab H.</creator><creator>Hazem, Noha M.</creator><creator>AbdElfattah, Amany A.</creator><creator>El-Kady, Rania A.</creator><creator>Elmasry, Ahlam</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9744-4609</orcidid></search><sort><creationdate>20220501</creationdate><title>Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression</title><author>Ashour, Rehab H. ; Hazem, Noha M. ; AbdElfattah, Amany A. ; El-Kady, Rania A. ; Elmasry, Ahlam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-a0cf8b46dfc9e68fb5b574e7f9aa38cda04e6493b2e360a0290034772f4154063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cell density</topic><topic>Colitis</topic><topic>Colon</topic><topic>Combined treatment</topic><topic>Crypts</topic><topic>Dextran</topic><topic>Dextran sulfate</topic><topic>Dextrans</topic><topic>Drugs</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Gene expression</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunohistochemistry</topic><topic>Immunosuppressive agents</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory bowel diseases</topic><topic>Interleukin 6</topic><topic>Interleukin-35</topic><topic>Ki67</topic><topic>Mucosa</topic><topic>Pentosan polysulfate</topic><topic>Sodium</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ashour, Rehab H.</creatorcontrib><creatorcontrib>Hazem, Noha M.</creatorcontrib><creatorcontrib>AbdElfattah, Amany A.</creatorcontrib><creatorcontrib>El-Kady, Rania A.</creatorcontrib><creatorcontrib>Elmasry, Ahlam</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ashour, Rehab H.</au><au>Hazem, Noha M.</au><au>AbdElfattah, Amany A.</au><au>El-Kady, Rania A.</au><au>Elmasry, Ahlam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>106</volume><spage>108620</spage><epage>108620</epage><pages>108620-108620</pages><artnum>108620</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•Pentosan polysulfate ameliorated clinical signs of experimental colitis in mice.•It preserved colon structure and enhanced the mucosal proliferative capacity.•It augmented the colonic expression of the anti-inflammatory IL-35 gene.•It showed colonic reduction of the pro-inflammatory cytokine “IL-6” concentration.•It showed more pounced effects upon combination with acetylsalicylic acid. Ulcerative colitis (UC) primarily affects the mucosa of the distal colon. Dysregulated immune response in genetically-prone persons is claimed to be responsible for chronic intestinal inflammation. This study aimed to explore the efficacy and the hematological effects of pentosan polysulfate sodium (PPS) in a dextran sulfate sodium (DSS)-induced colitis model. Forty C57BL/6 female mice were equally divided into five groups: control group, DSS-colitis group, DSS-colitis treated with 5-aminosalicylic acid, DSS-colitis treated with PPS, and DSS-colitis treated with both drugs. Disease activity index (DAI) and colon length were calculated. Colonic IL-6 and IL-35 levels were assayed by ELISA. IL-35 gene expression was evaluated by qRT-PCR. Colon tissue samples were examined by H&amp;E stain and immunohistochemistry (IHC) of Ki67. The colitis group subjected to combined treatment showed the best outcome with significant improvement of DAI and increased colon length. Colonic IL-6 was significantly lower in both PPS- and combination-treated groups accompanied by a significantly higher IL-35 level and its EBI3 subunit mRNA expression. However, the PPS-treated colitis group showed higher gene expression of IL-35 EBI3 subunit by 1.5-fold compared with the combined group. The colon mucosa and crypts were significantly preserved in mice treated with both drugs with the best Ki67 positive cell density. PPS is a safe and promising drug in the treatment of UC as it exerted the best positive effect on the anti-inflammatory IL-35 level and gene expression. However, superior improvement of DAI was seen when PPS was added to ASA with a greater mucosal proliferation and repair.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35247859</pmid><doi>10.1016/j.intimp.2022.108620</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-9744-4609</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1567-5769
ispartof International immunopharmacology, 2022-05, Vol.106, p.108620-108620, Article 108620
issn 1567-5769
1878-1705
language eng
recordid cdi_proquest_miscellaneous_2636142796
source Elsevier ScienceDirect Journals
subjects Cell density
Colitis
Colon
Combined treatment
Crypts
Dextran
Dextran sulfate
Dextrans
Drugs
Enzyme-linked immunosorbent assay
Gene expression
Immune response
Immune system
Immunohistochemistry
Immunosuppressive agents
Inflammatory bowel disease
Inflammatory bowel diseases
Interleukin 6
Interleukin-35
Ki67
Mucosa
Pentosan polysulfate
Sodium
Ulcerative colitis
title Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T10%3A40%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pentosan%20Polysulfate%20Sodium%20augments%20the%20therapeutic%20effect%20of%205-Aminosalicylic%20Acid%20in%20DSS%20colitis%20model;%20the%20role%20of%20IL-35%20expression&rft.jtitle=International%20immunopharmacology&rft.au=Ashour,%20Rehab%20H.&rft.date=2022-05-01&rft.volume=106&rft.spage=108620&rft.epage=108620&rft.pages=108620-108620&rft.artnum=108620&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2022.108620&rft_dat=%3Cproquest_cross%3E2636142796%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2658289138&rft_id=info:pmid/35247859&rft_els_id=S1567576922001047&rfr_iscdi=true